Loading
Niche diagnostic assays for rare metabolic disorders, distributed direct-to-lab.
Why surfaced. Single sell-side voice; reimbursement code expansion 2026-Q2 not yet modeled by consensus.
Direct from filings or deterministically calculated. Every metric carries a basis tag and links to its source(s).
Every fact and figure on this profile traces to one of these.
Filings the engine has indexed for this name.
What sell-side has done with this name. Drops and downgrades are why screens flag the name.
Memos that pass the data-quality gate get published here.